Neurofilament light-chain (NfL) protein is a blood-based marker of neuroaxonal injury. We sought to (1) compare plasma NfL levels in children with chronic kidney disease (CKD) and healthy peers, (2) characterize the relationship between NfL level and kidney function, and (3) evaluate NfL as a predictor of abnormal brain structure in CKD.
Sixteen children with CKD due to congenital kidney anomalies and 23 typically developing peers were included. Plasma NfL was quantified using single-molecule array immunoassay. Participants underwent structural magnetic resonance imaging. Multiple linear regression models were used to evaluate the association between plasma NfL levels, kidney function, and brain structure.
An age × group interaction was identified whereby NfL levels increased with age in the CKD group only (estimate = 0.65; confidence interval (CI) = 0.08–1.22; p = 0.026). Decreased kidney function was associated with higher NfL levels (estimate = −0.10; CI = −0.16 to −0.04; p = 0.003). Lower cerebellar gray matter volume predicted increased plasma NfL levels (estimate = −0.00024; CI = −0.00039 to 0.00009; p = 0.004) within the CKD group.
Children with CKD show accelerated age-related increases in NfL levels. NfL level is associated with lower kidney function and abnormal brain structure in CKD.
NfL is a component of the neuronal cytoskeleton providing structural axonal support. Elevated NfL has been described in relation to gray and white matter brain volume loss. We have previously described the abnormal cerebellar gray matter in CKD.
We explored the relationship between NfL, CKD, and brain volume.
There is an accelerated, age-related increase in NfL level in CKD. Within the CKD sample, NfL level is associated with abnormal kidney function and brain structure. Decreased kidney function may be linked to abnormal neuronal integrity in pediatric CKD.
Subscribe to Journal
Get full journal access for 1 year
only $30.69 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Anonymized data are not available in a public repository; however, it will be shared upon request from any qualified investigator.
Hooper, S. R. et al. Neurocognitive functioning of children and adolescents with mild-to-moderate chronic kidney disease. Clin. J. Am. Soc. Nephrol. 6, 1824–1830 (2011).
Mendley, S. R. et al. Duration of chronic kidney disease reduces attention and executive function in pediatric patients. Kidney Int. 87, 800–806 (2015).
Harshman, L. A. et al. Academic achievement in children with chronic kidney disease: a report from the CKiD cohort. Pediatr. Nephrol. https://doi.org/10.1007/s00467-018-4144-7 (2018).
Harshman, L. A. & Hooper, S. R. The brain in pediatric chronic kidney disease-the intersection of cognition, neuroimaging, and clinical biomarkers. Pediatr. Nephrol. 35, 2221–2229 (2020).
Johnson, R. J. et al. A longitudinal examination of parent-reported emotional-behavioral functioning of children with mild to moderate chronic kidney disease. Pediatr. Nephrol. 35, 1287–1295 (2020).
Solomon, M. A. et al. Early pediatric chronic kidney disease is associated with brain volumetric gray matter abnormalities. Pediatr. Res. https://doi.org/10.1038/s41390-020-01203-w (2020).
Disanto, G. et al. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann. Neurol. 81, 857–870 (2017).
Byrne, L. M. et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington’s disease: a retrospective cohort analysis. Lancet Neurol. 16, 601–609 (2017).
Thebault, S., Booth, R. A. & Freedman, M. S. Blood neurofilament light chain: the neurologist’s troponin? Biomedicines 8, https://doi.org/10.3390/biomedicines8110523 (2020).
Jakimovski, D. et al. Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study. Ann. Clin. Transl. Neurol. 6, 1757–1770 (2019).
White, N. et al. PROMO: real-time prospective motion correction in MRI using image-based tracking. Magn. Reson. Med. 63, 91–105 (2010).
Pierson, R. et al. Fully automated analysis using BRAINS: AutoWorkup. Neuroimage 54, 328–336 (2011).
Wang, H. et al. Multi-Atlas segmentation with joint label fusion. IEEE Trans. Pattern Anal. Mach. Intell. 35, 611–623 (2013).
Desikan, R. S. et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 31, 968–980 (2006).
Fortin, J. P. et al. Harmonization of cortical thickness measurements across scanners and sites. Neuroimage 167, 104–120 (2018).
Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8, 118–127 (2007).
Koscik, T. R. ez.combat. www.github.com/TKosik/ez.combat (2018).
Gray, E. et al. A multi-center study of neurofilament assay reliability and inter-laboratory variability. Amyotroph. Lateral Scler. Frontotemporal Degener. 21, 452–458 (2020).
Gaiottino, J. et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS ONE 8, e75091 (2013).
Kuhle, J. et al. A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult. Scler. 19, 1597–1603 (2013).
Keshavan, A., Heslegrave, A., Zetterberg, H. & Schott, J. M. Stability of blood-based biomarkers of Alzheimer’s disease over multiple freeze-thaw cycles. Alzheimers Dement. 10, 448–451 (2018).
Kuhle, J. et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin. Chem. Lab. Med. 54, 1655–1661 (2016).
Quanterix. Simoa NF-Light Advantage Kit: Kit Instructions for HD-1 (Quanterix Corporation, 2018).
Lenroot, R. K. et al. Sexual dimorphism of brain developmental trajectories during childhood and adolescence. Neuroimage 36, 1065–1073 (2007).
Kanaan, R. A. et al. Gender differences in white matter microstructure. PLoS ONE 7, e38272–e38272 (2012).
Vasung, L., Fischi-Gomez, E. & Huppi, P. S. Multimodality evaluation of the pediatric brain: DTI and its competitors. Pediatr. Radiol. 43, 60–68 (2013).
Barro, C., Chitnis, T. & Weiner, H. L. Blood neurofilament light: a critical review of its application to neurologic disease. Ann. Clin. Transl. Neurol. 7, 2508–2523 (2020).
Brown, T. T. & Jernigan, T. L. Brain development during the preschool years. Neuropsychol. Rev. 22, 313–333 (2012).
Akamine, S. et al. Renal function is associated with blood neurofilament light chain level in older adults. Sci. Rep. 10, 20350 (2020).
Korley, F. K. et al. Serum NfL (neurofilament light chain) levels and incident stroke in adults with diabetes mellitus. Stroke 50, 1669–1675 (2019).
Verbitsky, M. et al. Genomic disorders and neurocognitive impairment in pediatric CKD. J. Am. Soc. Nephrol. 28, 2303–2309 (2017).
Namm, A., Arend, A. & Aunapuu, M. Expression of Pax2 protein during the formation of the central nervous system in human embryos. Folia Morphol. 73, 272–278 (2014).
Suzuki, A., Harada, H. & Nakamura, H. Nuclear translocation of FGF8 and its implication to induce Sprouty2. Dev. Growth Differ. 54, 463–473 (2012).
Wang, V. Y. & Zoghbi, H. Y. Genetic regulation of cerebellar development. Nat. Rev. Neurosci. 2, 484–491 (2001).
Dziarmaga, A., Quinlan, J. & Goodyer, P. Renal hypoplasia: lessons from Pax2. Pediatr. Nephrol. 21, 26–31 (2006).
Martinovic-Bouriel, J. et al. PAX2 mutations in fetal renal hypodysplasia. Am. J. Med. Genet. A 152A, 830–835 (2010).
Zheng, Y. et al. The significance of Pax2 expression in the ureter epithelium of children with vesicoureteric reflux. Hum. Pathol. 46, 963–970 (2015).
de Miranda, D. M. et al. PAX2 polymorphisms and congenital abnormalities of the kidney and urinary tract in a Brazilian pediatric population: evidence for a role in vesicoureteral reflux. Mol. Diagn. Ther. 18, 451–457 (2014).
Boualia, S. K. et al. Vesicoureteral reflux and other urinary tract malformations in mice compound heterozygous for Pax2 and Emx2. PLoS ONE 6, e21529 (2011).
Bates, C. M. Role of fibroblast growth factor receptor signaling in kidney development. Am. J. Physiol. Ren. Physiol. 301, F245–F251 (2011).
This study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (K23DK110443—L.A.H.).
The authors declare no competing interests.
Informed consent and/or assent, as applicable, was obtained from participants and legal guardians at the time of participation.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
van der Plas, E., Lullmann, O., Hopkins, L. et al. Associations between neurofilament light-chain protein, brain structure, and chronic kidney disease. Pediatr Res (2021). https://doi.org/10.1038/s41390-021-01649-6